#United States #Charlotte #Nanoscope Therapeutics #Retina #Samarendra Mohanty

Nanoscope Therapeutics to Spotlight Vision Restoration at ISPE 2025

Nanoscope Therapeutics Inc., a pioneering force in biotechnology, is gearing up for a significant presence at the 2025 ISPE Annual Meeting and Expo. Scheduled to take place from October 26-29, 2025, in Charlotte, North Carolina, the event will feature Dr. Samarendra Mohanty, the company's President and Chief Scientific Officer, as a distinguished speaker. Dr. Mohanty's participation signifies Nanoscope's commitment to addressing critical vision impairment issues, particularly those resulting from retinal degeneration.

Nanoscope Therapeutics is at the forefront of developing innovative therapies aimed at treating patients facing photoreceptor loss—specifically conditions like retinitis pigmentosa (RP) and Stargardt disease (SD). These diseases currently lack approved therapeutic options, making Nanoscope's work vital for improving patient outcomes.

Presentations and Discussions

During the meeting, Dr. Mohanty will deliver two key presentations, alongside engaging in a panel discussion focusing on innovative approaches within the landscape of gene therapy in decentralized clinical trials. One of his presentations will address the Multi-Characteristic Opsin (MCO) platform, a groundbreaking method designed to restore vision for patients suffering from severe vision loss. This novel therapy not only holds promise for treating RP and SD but also offers a one-time solution without the need for genetic testing, invasive procedures, or repetitive treatments.

Event Details:

• - Event: ISPE Annual Meeting and Expo
• - Date/Time:

- Panel Discussion: The Future of CGT Innovations in Decentralized Clinical Trials and Technological Advancements
- Date: Monday, October 27, 2025
- Time: 4:15 PM - 5:45 PM EDT
- Location: Charlotte Convention Center, Room E220CD
- Presentation: Challenges in Developing Mutation-Agnostic Gene Therapy Approaches
- Date: Tuesday, October 28, 2025
- Time: 3:45 PM - 4:30 PM EDT
- Location: Charlotte Convention Center, Room E219AB

Nanoscope's Vision Restoring MCO Platform

The MCO platform represents a significant advancement in the field of optogenetics, particularly given its ability to transform remaining viable retinal cells into a means of restoring vision. This technology aims to harness the remaining functional retinal circuitry through the targeted activation of bipolar retinal cells. Since it is designed to be utilized in standard settings, catering to a wide variety of patients without extensive prerequisites, the future applicability of MCO therapy appears bright.

Notably, following the promising results from the recent RESTORE Phase 2b/3 clinical trial for RP, Nanoscope has initiated a rolling Biological License Application (BLA) submission to the FDA. If successful, this could pave the way for MCO-010 to establish itself as the standard treatment for patients battling RP. Furthermore, ongoing examinations in Stargardt disease are expected to yield beneficial results, enhancing treatment options for countless individuals.

Conclusion

As Nanoscope Therapeutics prepares for a significant showcase at ISPE 2025, Dr. Mohanty’s presentations signal a pivotal moment in ophthalmic therapy and biotechnological innovations. By addressing challenges in mutation-agnostic approaches, Nanoscope is positioned to lead transformative changes in how retinal degeneration is treated, potentially improving lives and restoring hope for many facing these debilitating conditions. Stay tuned for insights and developments that could redefine the horizon of vision restoration.

For more information, you may reach Nanoscope Therapeutics at (817) 857-1186 or visit their website.